D H M Bodden1, Y Stikkelbroek2, C D Dirksen3. 1. Department of Child and Adolescent Studies, Utrecht University, Utrecht, The Netherlands. Electronic address: d.bodden@uu.nl. 2. Department of Child and Adolescent Studies, Utrecht University, Utrecht, The Netherlands; GGZ Oost Brabant, Boekel, The Netherlands. 3. Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center, Care and Public Health Research Institute (CAPHRI), Maastricht, The Netherlands.
Abstract
BACKGROUND: Depression in adolescents is a serious problem to society because of the high prevalence rate, the high subjective burden of illness and negative (economic) consequences. Information regarding the economic burden of adolescent depression is scarce. The goal of this study is twofold. First, an overview of the literature on prevalence, burden of disease, and costs related to adult and adolescent depression is given. Second, a prevalence-based cost-of-illness study is being conducted. METHODS: In this study a cost-of-illness study using a societal perspective was conducted using data of 56 clinically depressed Dutch adolescents aged 12-21. Bottom-up acquired costs were measured by means of cost questionnaires. RESULTS: The calculations showed that clinically depressed adolescents referred to treatment cost the Dutch society €37.7 million a year. The calculated costs were higher when a more recent prevalence rate was used in a secondary analysis. LIMITATIONS: Limitations of this study are that only older Dutch prevalence rates were available, a relatively small sample size was used and no long term costs could be calculated. CONCLUSION: Even though the sample size is small, the calculated costs are indicative for the societal costs of adolescents with depression. Cost-effective prevention and intervention methods seem warranted to reduce these enormous costs.
BACKGROUND:Depression in adolescents is a serious problem to society because of the high prevalence rate, the high subjective burden of illness and negative (economic) consequences. Information regarding the economic burden of adolescent depression is scarce. The goal of this study is twofold. First, an overview of the literature on prevalence, burden of disease, and costs related to adult and adolescent depression is given. Second, a prevalence-based cost-of-illness study is being conducted. METHODS: In this study a cost-of-illness study using a societal perspective was conducted using data of 56 clinically depressed Dutch adolescents aged 12-21. Bottom-up acquired costs were measured by means of cost questionnaires. RESULTS: The calculations showed that clinically depressed adolescents referred to treatment cost the Dutch society €37.7 million a year. The calculated costs were higher when a more recent prevalence rate was used in a secondary analysis. LIMITATIONS: Limitations of this study are that only older Dutch prevalence rates were available, a relatively small sample size was used and no long term costs could be calculated. CONCLUSION: Even though the sample size is small, the calculated costs are indicative for the societal costs of adolescents with depression. Cost-effective prevention and intervention methods seem warranted to reduce these enormous costs.
Authors: Denise H M Bodden; Marieke W H van den Heuvel; Rutger C M E Engels; Carmen D Dirksen Journal: J Child Psychol Psychiatry Date: 2021-09-08 Impact factor: 8.265
Authors: Marieke W H van den Heuvel; Denise H M Bodden; Mirjam Moerbeek; Filip Smit; Rutger C M E Engels Journal: BMC Psychiatry Date: 2019-06-27 Impact factor: 3.630
Authors: Guan-Hao He; Esben Strodl; Wei-Qing Chen; Fan Liu; Alimila Hayixibayi; Xiang-Yu Hou Journal: Int J Environ Res Public Health Date: 2019-06-20 Impact factor: 3.390
Authors: Anna Philipson; Iman Alaie; Richard Ssegonja; Henrik Imberg; William Copeland; Margareta Möller; Lars Hagberg; Ulf Jonsson Journal: Epidemiol Psychiatr Sci Date: 2020-04-29 Impact factor: 6.892
Authors: Andrew Beck; John C LeBlanc; Kate Morissette; Candyce Hamel; Becky Skidmore; Heather Colquhoun; Eddy Lang; Ainsley Moore; John J Riva; Brett D Thombs; Scott Patten; Heather Bragg; Ian Colman; Gary S Goldfield; Stuart Gordon Nicholls; Kathleen Pajer; Beth K Potter; Robert Meeder; Priya Vasa; Brian Hutton; Beverley J Shea; Eva Graham; Julian Little; David Moher; Adrienne Stevens Journal: Syst Rev Date: 2021-01-12
Authors: Irina Pokhilenko; Luca M M Janssen; Silvia M A A Evers; Ruben M W A Drost; Lena Schnitzler; Aggie T G Paulus Journal: Pharmacoeconomics Date: 2021-06-14 Impact factor: 4.981